Evaluating patient and clinical outcomes after cardiac surgery
Clinical Protocol REN-007E - Extension Study: An Evaluation of Patient Reported Outcomes and Clinical Outcomes Through 12 Months Post-Cardiac Surgery in Subjects Enrolled in Study REN-007
This study looks at how people feel and their health after heart surgery to see how well they recover over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Renibus Therapeutics, Inc. Industry-sponsored |
| Locations | 39 sites (Huntsville, Alabama and 38 other locations) |
| Trial ID | NCT06092970 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess patient-reported outcomes and clinical outcomes in individuals who have undergone cardiac surgery. Participants will complete the EQ-5D questionnaire to evaluate their quality of life and other health-related metrics over a 12-month period following surgery. The study will include data from patients who previously participated in the REN-007 study, allowing for a comprehensive analysis of post-operative recovery and complications. The focus is on understanding both subjective and objective measures of health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who have completed the REN-007 study and have undergone cardiac surgery.
Not a fit: Patients who did not complete the REN-007 study or who become pregnant during that study will not benefit from this extension study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the recovery process after cardiac surgery, potentially leading to improved patient care and management strategies.
How similar studies have performed: Other studies evaluating patient-reported outcomes in surgical populations have shown success, indicating that this approach is both relevant and potentially beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects must have completed the REN-007 study to be eligible to participate in the Extension Study. Exclusion Criteria: * Subjects who did not complete the REN-007 study are not eligible to participate in the Extension Study. * Female subjects who become pregnant during the REN-007 study are not eligible to participate in the Extension Study.
Where this trial is running
Huntsville, Alabama and 38 other locations
- Research Site — Huntsville, Alabama, United States (Recruiting)
- Research Site — San Francisco, California, United States (Recruiting)
- Research Site — Stanford, California, United States (Recruiting)
- Research Site — Washington, District of Columbia, United States (Recruiting)
- Research Site — Atlantis, Florida, United States (Recruiting)
- Research Site — Gainesville, Florida, United States (Recruiting)
- Research Site — Athens, Georgia, United States (Recruiting)
- Research Site — Atlanta, Georgia, United States (Recruiting)
- Research Site — Fort Wayne, Indiana, United States (Recruiting)
- Research Site — Indianapolis, Indiana, United States (Recruiting)
- Research Site — Indianapolis, Indiana, United States (Recruiting)
- Research Site — Kansas City, Kansas, United States (Recruiting)
- Research Site — Boston, Massachusetts, United States (Recruiting)
- Research Site — Ann Arbor, Michigan, United States (Recruiting)
- Research Site — Lansing, Michigan, United States (Recruiting)
- Research Site — Midland, Michigan, United States (Recruiting)
- Research Site — Royal Oak, Michigan, United States (Recruiting)
- Research Site — Rochester, Minnesota, United States (Recruiting)
- Research Site — Saint Louis, Missouri, United States (Recruiting)
- New York Presbyterian-Queens — Flushing, New York, United States (Recruiting)
- Research Site — Raleigh, North Carolina, United States (Recruiting)
- Research Site — Winston-Salem, North Carolina, United States (Recruiting)
- Research Site — Cleveland, Ohio, United States (Recruiting)
- Research Site — Toledo, Ohio, United States (Recruiting)
- Research Site — Nashville, Tennessee, United States (Recruiting)
- Research Site — Dallas, Texas, United States (Recruiting)
- Research Site — Houston, Texas, United States (Recruiting)
- Research Site — San Antonio, Texas, United States (Recruiting)
- Research Site — Charlottesville, Virginia, United States (Recruiting)
- Research Site — Kelowna, British Columbia, Canada (Recruiting)
- Research Site — Saint John, New Brunswick, Canada (Recruiting)
- Research Site — Saint John's, Newfoundland and Labrador, Canada (Recruiting)
- Research Site — Hamilton, Ontario, Canada (Recruiting)
- Research Site — Kingston, Ontario, Canada (Recruiting)
- Research Site — Montréal, Quebec, Canada (Recruiting)
- Research Site — Montréal, Quebec, Canada (Recruiting)
- Research Site — Montréal, Quebec, Canada (Recruiting)
- Research Site — Montréal, Quebec, Canada (Recruiting)
- Research Site — Québec, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Jennifer Paleveda
- Email: jpaleveda@renibus.com
- Phone: 813-760-3975
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.